In vitro profiling of apixaban, betrixaban, edoxaban, and rivaroxaban demonstrated that their measured anti-Xa activity alone does not fully reflect their overall biologic and anticoagulant spectrum.
The biologic spectrum and global anticoagulant effects of different anti-Xa agents vary significantly and are not solely reflected by their anti-Xa inhibitory potency.
The currently available oral anti-Xa agents are claimed to produce their anticoagulant and antithrombotic effects solely by the inhibition of factor Xa. This study profiled various anti-Xa drugs in routinely used laboratory assays to demonstrate that their effects are not solely related to the anti-Xa activities. Apixaban, betrixaban, edoxaban, and rivaroxaban were obtained commercially. Native and citrated whole blood was used for the activated clotting time (ACT) and thromboelastography (TEG). Citrated plasma was used for monitoring the prothrombin time (PT), activated partial thromboplastin time (aPTT), Heptest, and prothrombinase-induced clotting time (PiCT) tests. An amidolytic method was used for the determination of anti-Xa effects. Thrombin-induced fibrinokinetics was monitored optically. Thrombin generation studies were carried out using the calibrated automated thrombogram. All of the anti-Xa agents produced concentration- and assay-dependent effects. In the ACT at 2.5 μg/mL and TEG at 1.0 μg/mL, edoxaban exhibited the strongest anticoagulation effect. In the PiCT, PT, and aPTT assay at 1 μg/mL, edoxaban showed stronger effects than other agents. The half maximal inhibitory concentration of these agents for the inhibition of factor Xa ranged from 340 to >1000 ng/mL. In the thrombin generation inhibition assay, apixaban showed the strongest activity. In the fibrinokinetics, different anti-Xa agents produced varying degrees of inhibition. These results demonstrate that the measured anti-Xa activity alone does not fully reflect the overall biologic spectrum of these agents.
Siddiqui et al. (2019) studied Healthy donors (in vitro blood samples) (n=7). Direct oral anti-Xa agents (apixaban, betrixaban, edoxaban, rivaroxaban) vs. Saline control was evaluated on Anticoagulant effects in various laboratory assays (ACT, TEG, PiCT, aPTT, PT, anti-Xa, thrombin generation). In vitro profiling of apixaban, betrixaban, edoxaban, and rivaroxaban demonstrated that their measured anti-Xa activity alone does not fully reflect their overall biologic and anticoagulant spectrum.